Cognition Capital Surpluse from 2010 to 2025

CGTX Stock  USD 0.45  0.01  2.17%   
Cognition Therapeutics Capital Surpluse yearly trend continues to be fairly stable with very little volatility. Capital Surpluse will likely drop to about 124.7 M in 2025. During the period from 2010 to 2025, Cognition Therapeutics Capital Surpluse regression line of annual values had r-squared of  0.31 and arithmetic mean of  152,898,375. View All Fundamentals
 
Capital Surpluse  
First Reported
2010-12-31
Previous Quarter
140.2 M
Current Value
124.7 M
Quarterly Volatility
8.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cognition Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cognition Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 215.5 K, Interest Expense of 23.1 K or Selling General Administrative of 9.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.14. Cognition financial statements analysis is a perfect complement when working with Cognition Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cognition Therapeutics Correlation against competitors.
For more information on how to buy Cognition Stock please use our How to Invest in Cognition Therapeutics guide.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cognition Stock Analysis

When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.